127 related articles for article (PubMed ID: 9271323)
1. IL-6 is a survival prognostic factor in renal cell carcinoma.
Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
3. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
5. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
[No Abstract] [Full Text] [Related]
8. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J
Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
13. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2005 Aug; 20(4):410-6. PubMed ID: 16114989
[TBL] [Abstract][Full Text] [Related]
14. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
15. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
19. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]